Bioengineering a needle-free intranasal nanovaccine with TLR7/8 agonist for potent antimetastatic immunity

Su Yeon Lim – Postdoctoral reseacher, SUNGKYUNKWAN UNIVERSITY; Dahwun Kim – Doctoral reseacher, SUNGKYUNKWAN UNIVERSITY; Ji Hoon Jeong – Professor, SUNGKYUNKWAN UNIVERSITY

Introduction: Recent outbreaks of infectious diseases highlight the need for mucosal vaccines capable of inducing both mucosal and systemic immunity, as conventional systemic vaccines often provide insufficient protection. Here, we developed a needle-free intranasal nanovaccine based on a cationic polymeric carrier (DA3), composed of secondary bile acid–conjugated polyethyleneimine, for co-delivery of resiquimod (R848) and ovalbumin (OVA). DA3/R848/OVA nanoparticles are formed via hydrophobic and ionic interactions, enhancing antigen stability and immune responses. These findings suggest DA3-based nanovaccines as a promising and safe platform for needle-free cancer immunotherapy.